Novo Nordisk is mentioned as a competitor in the GLP-1 drug market, with Viking Therapeutics' drug performing similarly to theirs and potential acquisition interest.
Source Post
Steve D's Q3 Portfolio Update
Oct 4, 2026
The creator provides a Q3 portfolio update, noting underperformance compared to indices like the S&P 500 and VWRP. They discuss portfolio additions, sales, and individual stock performance, highlighting both strong performers and laggards. The creator mentions having 34 positions and expresses a need to trim the portfolio size.
Linked Mentions
Tickers discussed in this post
Eli Lilly is mentioned as a competitor in the GLP-1 drug market, with Viking Therapeutics' drug performing similarly to theirs.
Viking Therapeutics (VKTX) is an interesting name to watch, with its GLP-1 drug showing promise and the current valuation presenting a significant growth opportunity.
Grainger, now clearly a REIT, is down about 15%, making it an interesting opportunity to increase exposure.
Realty Income has hit a 52-week low with a 10-year high dividend yield, making it attractive for potential investment.
PayPal is identified as a loser in the payments sector, implying a negative outlook.
Prologis is mentioned as a portfolio holding.
Next is mentioned as a portfolio holding.
NXP Semiconductors is mentioned as a portfolio holding.
The creator sold Nike, feeling they had too many stocks and that it was 'dead money', with better places for their capital.
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.